Tumor Microenvironment‐responsive Nanocatalyst for Targeted Chemodynamic Cancer Therapy
Advanced Healthcare Materials · 2025-08 · 14 (22)
DOI: 10.1002/adhm.202501746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 17.06.2025. Verfasst von Jun Ma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Texas A&M University, College Station, TX, 77843, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, Nanoparticles, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To address the challenges of insufficient hydrogen peroxide (H 2 O 2 ) levels, rapid Fe 3+ precipitation, and a slow Fenton reaction cycle, tumor‐activated, self‐accelerating CDT nanocatalysts are synthesized, comprising poly (lactic‐co‐glycolic acid) (PLGA)‐encapsulated Ca‐Fe peroxide clusters and polyarginine (R). Nanocatalysts are camouflaged with cancer cell membranes (CCM) to enhance tumor targeting. Additionally, polyarginine tailored the PLGA responsiveness to low H 2 O 2 levels (50–100 µ m ). H 2 O 2 triggered the degradation of PLGA, releasing CaFe clusters to produce Fe 3+ /Fe 2+ and additional H 2 O 2 , sustaining the Fenton reaction. Simultaneously, polyarginine releases nitric oxide (NO) in the presence of H 2 O 2 , facilitating Fe 3+ reduction to Fe 2+ and amplifying •OH generation. In vitro cellular studies demonstrate significantly improved homotypic tumor targeting (6.5‐fold increase) and deep spheroid penetration (>120 µm), resulting in improved tumor permeability and elevated •OH generation. Additionally, the nanoparticles exhibit dose‐dependent cytotoxicity, and polyarginine notably enhanced the cytotoxicity of CCM‐PLGA‐CaFe NPs, reducing the IC50 value from 216.9 to 43.38 µg mL −1 . Apoptosis/necrosis assay reveals that the elevated •OH generation by CCM‐PLGA‐CaFe‐R NPs preferentially induced necrosis, effectively inhibiting tumor cell proliferation by 76.3% ± 8.4% over a 7‐day treatment. Consequently, this TME‐responsive, self‐accelerating CDT platform demonstrates enhanced therapeutic efficacy through improved tumor targeting, sustained Fenton reaction, and amplified radical generation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Texas A&M University, College Station, TX, 77843, USA.
- Department of Mechanical Engineering, Texas A&M University, College Station, TX, 77843, USA.
- Department of Industrial Systems and Engineering, Texas A&M University, College Station, TX, 77843, USA.
- Department of Materials Science and Engineering, Texas A&M University, College Station, TX, 77843, USA.
ORCID-Profile: Shiren Wang
Zitieren
APA
Ma, J., Qiu, J., & Wang, S. (2025). Tumor Microenvironment‐responsive Nanocatalyst for Targeted Chemodynamic Cancer Therapy. Advanced Healthcare Materials, 14(22). https://doi.org/10.1002/adhm.202501746
Vancouver
Ma J, Qiu J, Wang S. Tumor Microenvironment‐responsive Nanocatalyst for Targeted Chemodynamic Cancer Therapy. Advanced Healthcare Materials. 2025;14(22). doi:10.1002/adhm.202501746
BibTeX
@article{Ma2025,
author = {Ma, Jun and Qiu, Jingjing and Wang, Shiren},
title = {Tumor Microenvironment‐responsive Nanocatalyst for Targeted Chemodynamic Cancer Therapy},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {22},
doi = {10.1002/adhm.202501746}
}
EUVIMED